---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-129824"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2023-12-28T23:59:59+00:00"
generated_at: "2026-06-07T06:21:58.134308+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Theravance settles YUPELRI patent litigation with Accord; generic entry allowed no earlier than April 23, 2039

## Summary
- Settlement Agreement with Accord resolves Hatch-Waxman litigation over YUPELRI inhalation solution.
- Accord granted royalty-free license to market generic YUPELRI on or after April 23, 2039, subject to customary exceptions.
- Settlement subject to review by U.S. Department of Justice and Federal Trade Commission.
- Patent litigation continues against five other ANDA filers: Cipla, Eugia, Lupin, Mankind, and Orbicular.

## SEC filing metadata
- accession: 0001104659-23-129824
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2023-12-28T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465923129824/0001104659-23-129824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465923129824/tm2333786d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-129824
- JSON: https://secwatch.observer/filing/0001104659-23-129824.json
- Plain text: https://secwatch.observer/filing/0001104659-23-129824.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.